• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sequencing Considerations in Relapsed/Refractory CLL

Opinion
Video

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.

Video content above is prompted by the following:

  • What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
  • How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?

Related Videos
Frederick L. Locke, MD
2 experts in this video
2 experts in this video
Dr Rebecca Haberman
1 expert is featured in this series.
Dr Rebecca Haberman
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.